STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid TumorsNavin Pinto, Julie R. Park, Jason Wendler et al.|Journal of Clinical Oncology|2024Cited by 46
First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastomaNavin Pinto, Julie R. Park, Annette Künkele et al.|Research Square|2024Cited by 4
The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed NeuroblastomaNavin Pinto, Julie R. Park, Annette Künkele et al.|Clinical Cancer Research|2026Cited by 0